Esophageal cancer is one of the leading causes of cancer-related deaths worldwide, with approximately 600,000 cases per year globally, making it the seventh most common cancer and the sixth deadliest cancer. At Alfa Cytology, we are committed to helping our clients unravel the complexity of esophageal cancer by providing integrated preclinical research solutions.
Introduction to Esophagus Cancer
Esophageal cancer arises when abnormal cells in the esophagus undergo uncontrolled growth, forming tumors. Esophageal cancer has a poor prognosis due to late diagnosis, with a low 5-year survival rate of 21.6%.
Fig.1 5-Year Relative Survival of Esophageal Cancer. (Credit the National Cancer Institute as the source.)
Types of Esophagus Cancer
There are two main types of esophageal cancer.
- Squamous Cell Carcinoma: Squamous cell carcinoma typically affects the upper and middle parts of the esophagus;
- Adenocarcinoma: Adenocarcinoma occurs in the lower part, near the junction with the stomach.
Therapy Development for Esophagus Cancer
The prevalence of esophageal cancer has indeed been increasing, leading to a greater demand for effective treatment options. This rise in prevalence has spurred considerable research and development efforts in the field, with numerous participants actively working on the development of potential therapies. As of now, there are over 80 active participants involved in the development of more than 90 pipeline therapies specifically targeting esophageal cancer.
The increasing prevalence of esophageal cancer has stimulated a significant research and development effort, with numerous participants actively working on the development of pipeline therapies. Continued research and collaborations are vital to advancing these therapies and ultimately providing more effective therapeutic options for individuals affected by esophageal cancer.
| Treatment Regimen |
Clinical Phase |
Clinical Trials.gov Identifier |
| EGFR-targeted |
| Icotinib |
II |
NCT01855854 |
| SCT200 |
I/II |
NCT03817567 |
| Cetuximab |
II |
NCT00096031 |
| Cetuximab, ECF, IC, FOLFOX |
II |
NCT00381706 |
| Cetuximab, paclitaxel, carboplatin |
II |
NCT00439608 |
| Cetuximab plus radiation |
II |
NCT02123381 |
| HER2-targeted |
| Pertuzumab, trastuzumab |
I/II |
NCT02120911 |
| Pembrolizumab, trastuzumab, and chemotherapy |
II |
NCT02954536 |
| mFOLFOX6+trastuzumab+avelumab |
II |
NCT03783936 |
| VEGF-targeted |
| Bevacizumab |
I |
NCT02072720 |
| Bevacizumab-IRDye800CW, Molecular fluorescence endoscopy platform |
I |
NCT03558724 |
| Regorafenib, paclitaxel |
I/II |
NCT02406170 |
Our Services
At Alfa Cytology, our mission is to make a significant impact in the fight against esophageal cancer by providing comprehensive and state-of-the-art services. We are dedicated to staying at the forefront of innovation and excellence, offering advanced technologies and methodologies in our diagnostic, therapeutic, and monitoring approaches.
Our services include but are not limited to:
Therapeutic Development Platform
At Alfa Cytology, we are committed to being at the forefront of esophageal cancer research and development, offering comprehensive and cutting-edge solutions for the management of this challenging disease. Our dedicated team of experts, state-of-the-art facilities, and extensive experience in preclinical studies, biomarker discovery, and clinical trials enable us to provide invaluable services to our clients.
If you would like more information about our esophageal cancer research and development initiatives, or if you have any inquiries about our comprehensive services, please don't hesitate to contact us.
! For research use only.
Related Services
